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Serum amyloid A (SAA) is a small apolipoprotein that binds to
high-density lipoproteins in the serum. Although SAA seems to
play a role in host defense and lipid transport and metabolism, its
specific functions have not been defined. Despite the growing
implications that SAA plays a role in the pathology of various
diseases, a high-resolution structure of SAA is lacking because
of limited solubility in the high-density lipoprotein-free form. In
this study, complementary methods including glutaraldehyde
cross-linking, size-exclusion chromatography, and sedimentation-
velocity analytical ultracentrifugation were used to show that
murine SAA2.2 in aqueous solution exists in a monomer–hexamer
equilibrium. Electron microscopy of hexameric SAA2.2 revealed
that the subunits are arranged in a ring forming a putative central
channel. Limited trypsin proteolysis and mass spectrometry anal-
ysis identified a significantly protease-resistant SAA2.2 region
comprising residues 39–86. The isolated 39–86 SAA2.2 fragment
did not hexamerize, suggesting that part of the N terminus is
involved in SAA2.2 hexamer formation. Circular-dichroism spec-
trum deconvolution and secondary-structure prediction suggest
that SAA2.2 contains 50% of its residues in -helical conforma-
tion and <10% in -structure. These findings are consistent with
the recent discovery that human SAA1.1 forms a membrane chan-
nel and have important implications for understanding the 3D
structure, multiple functions, and pathological roles of this highly
conserved protein.
Serum amyloid A (SAA) proteins are a family of apolipopro-teins found predominantly associated with high-density li-
poprotein (HDL) in plasma (1), with different isoforms being
unequally expressed constitutively and in response to inflam-
matory stimuli (2). Although synthesized primarily in the liver,
extrahepatic tissuecellular expression of SAA has been widely
documented (3). SAA has been linked to functions related to
inflammation, pathogen defense, HDL metabolism, and choles-
terol transport and thereby has been implicated (3) in several
pathological conditions including atherosclerosis, rheumatoid
arthritis, Alzheimer’s disease, and cancer.
SAA is known best for its role during the acute phase response
to an inflammatory stimulus such as infection, tissue injury, and
trauma (2). During active inflammation the concentration of
SAA in plasma can increase up to 1,000-fold within 24 h (4). It
is believed that persistently high levels of SAA during chronic
inflammation may contribute to the occasional development
of the potentially fatal disease reactive amyloidosis [amyloid A
(AA) amyloidosis] (5). In AA amyloidosis, AA, an N-terminal
(1–76) fragment of SAA (6), frequently is found to form amyloid
deposits in the liver, kidney, and spleen. However, the presence,
in vivo, of full-length SAA in amyloid deposits (7) and the ability
of various SAA isoforms to form fibrils in vitro (8–10) suggest
that proteolytic cleavage may not be a prerequisite for AA
deposition but rather a postdeposition event. Of the three loci that
express SAA in humans, SAA1 is the major, although not the only,
precursor of AA deposits (11). Similarly, type A (i.e., BALBc)
mice contain two SAA isoforms, SAA2.1 and SAA1.1 [formerly
known as SAA1 and SAA2, respectively (12)], of which only the
latter deposits into amyloid after chronic inflammation induced
with casein or azocasein (13). In contrast, the CEJ mouse strain
produces a single SAA isoform, SAA2.2 (formerly known as
SAA CEJ), which is amyloid-resistant (14, 15).
Although the exact in vivo functions of SAA are still obscure,
its high conservation from fish to humans (16), wide expression
profile in tissuescells, and dramatic increase in expression levels
during the acute phase response suggest a fundamental protec-
tive role for SAA. Yet, despite its small size (12 kDa) and highly
significant functions, there is very limited structural information
about SAA because of its inherent poor solubility in the apoli-
poprotein form. It is intriguing to understand how such a small
protein is able to mediate or directly carry out such a wide range
of functions related to inflammatory reaction and other host-
defense mechanisms (3). The various functions of SAA may be
modulated by factors such as conformational changes induced by
ligand binding or by the ability to adopt more than one oligo-
meric state. Deciphering the molecular basis of the functional
and potentially pathological properties of SAA will require
understanding its structure under various conditions. In this
study, we make a significant advancement toward understanding
the structure of SAA, as we show by various methods that murine
SAA2.2 can exist in aqueous solution as a hexamer containing
a putative central channel.
Materials and Methods
SAA2.2 Expression and Purification. The murine SAA2.2 cDNA was
cloned into a pET21-a() vector between the NdeI and BamHI
sites and transformed into Escherichia coli strain BL21 (DE3)
pLysS-competent cells as described (17). Cells were lysed in
2-amino-2-hydroxymethyl-1,3-propanediol (Tris) buffer (20
mM, pH 8.2) by three consecutive freezing-thawing cycles, and
the lysate was added gradually to buffer A (Tris buffer6 M urea)
and concentrated by ultrafiltration before loading onto a DEAE
anion-exchange column (Sigma). SAA2.2 was eluted by a linear
gradient of 20–100% buffer B (buffer A0.4 M NaCl), and the
fractions were pooled and desalted by several cycles of ultrafil-
tration using buffer A. SAA2.2 was purified further by chro-
matofocusing as described (8). The resulting fractions were
precipitated with a 70% (final concentration) saturated ammo-
nium sulfate solution, and the dissolved pellet was dialyzed
against Tris buffer (pH 8.2) or 6 mM PBS (7.4) at 4°C.
Glutaraldehyde Cross-Linking (GCL). SAA2.2 samples (0.1 mgml)
in PBS were incubated at room temperature (20–22°C) for 20
min in various glutaraldehyde (Sigma) concentrations ranging
from 0.006% to 0.6% (wtvol). The cross-linking reaction was
quenched by adding Tris buffer from a concentrated (1 M) stock
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solution to a final concentration of 0.1 M. The cross-linked
SAA2.2 samples were analyzed by SDSPAGE.
HPLC. Reverse-phase (RP) HPLC was carried out on a Gold
Noveau Beckman Coulter instrument, by using an analytic
4.6-mm-i.d. C4-RP column (Vydac, Hesperia, CA) running at
0.66 mlmin. A 5–90% linear gradient [0.1% (vol/vol) trif luoro-
acetic acid90% (vol/vol) acetonitrile aqueous solution] was
applied, and the column was regenerated with a 0.1% trif luoro-
acetic acid aqueous solution. Size-exclusion chromatography
(SEC) experiments were performed on a Superdex 75 PC 3.230
column (Amersham Pharmacia) equilibrated with buffer B at a
flow rate of 0.05 mlmin. The signal was monitored at 220 nm.
Limited Trypsin Proteolysis. Experiments were performed at room
temperature by using SAA2.2 samples (0.4 mgml) in Tris buffer
(20 mM, pH 8.2) and a trypsinSAA2.2 ratio of 1:120 (wtwt).
The proteolysis was quenched at various reaction times by adding
0.1% (volvol) trif luoroacetic acid or 1 mM phenylmethylsulfo-
nyl f luoride. Subsequent RP-HPLC and mass spectrometry
(MS) analysis of the SAA2.2 trypsin digest were performed after
a 4-fold dilution in Tris buffer to generate 0.1 mgml SAA2.2
samples.
MS. Liquid chromatographyelectrospray MS services were pro-
vided by The W. M. Keck Biotechnology Resource Center at
Yale University (New Haven, CT). Liquid chromatographyMS
analysis was done in a Finnigan-MAT (San Jose, CA) LCQ
quadrupole ion-trap mass spectrometer connected to an auto-
mated HPLC system with a 300-m 25-cm Vydac C18 column
running at 3 lmin.
Circular Dichroism (CD). CD spectra were recorded on an OLIS
(Bogart, GA) CD instrument. Data were collected in a 0.1-cm
pathway quartz cuvette at 20°C. Secondary (2°) structure analysis
from the CD spectra of SAA2.2 (0.1 mgml) and its fragment
from residues 39 to 86 (SAA39–86, 0.17 mgml) in Tris buffer
was carried out by using the programs CONTINLL, CDSSTR, and
SELCON3 using a wavelength range of 190–240 nm and a refer-
ence set of 43 proteins (18).
Sedimentation-Velocity Analytical Ultracentrifugation. Sedimenta-
tion-velocity data were collected in a Beckman Coulter XL-A
centrifuge. A double-sector cell, equipped with a 12-mm Epon
centerpiece and quartz windows, was loaded with 400 l of
SAA2.2 sample (0.27 mgml in 50 mM Tris, pH 8.2150 mM
NaCl). Data were collected at rotor speeds of 3,000–60,000
rpm in continuous mode at 25°C, with a step size of 0.005 cm
and an average of 3 scans per point. The sedimentation-
velocity absorbance profiles were analyzed to obtain the
apparent distribution of sedimentation coefficients g(s*) for
all the quaternary structures in solution by using the DCDT
software provided by J. S. Philo (19). The partial specific-
volume value of 0.71 cm3g was determined based on the
SAA2.2 amino acid sequence (20).
Electron Microscopy (EM) and Image Processing. SAA2.2 (purified
by gel filtration) was adsorbed to glow-discharged carbon-coated
copper grids at 4°C. Grids were washed with two drops of
deionized water and stained with two drops of freshly prepared
0.75% uranyl formate. Specimens were inspected with a Philips
Tecnai 12 electron microscope operated at 120 kV, and images
were taken at a nominal magnification of 52,000 by using
low-dose procedures. For image processing, 12 images were
digitized with a Zeiss SCAI scanner using a pixel size of 4.04 Å
at the specimen level. From the digitized images, 6,959 particles
were selected and subjected to multireference alignment and
image-classification procedures by using the SPIDER image-
processing package (21).
Results
SAA2.2 Is a Hexamer in Solution. Because of its inherent tendency
to self-assemble, it is not clear whether SAA carries out its
various functions as a monomeric species or a higher oligomer.
However, because of its multifunctional role, we hypothesized
that SAA may function in more than one oligomeric state. The
increased solubility of the murine SAA2.2 variant provides an
opportunity to investigate the oligomeric state of the apolipopro-
tein in vitro. To determine the quaternary structure of SAA2.2
in solution, several complementary methods were used including
GCL, SEC, sedimentation-velocity analytical ultracentrifuga-
tion, and EM. Glutaraldehyde reacts with the amino group of
lysine side chains and therefore has been used extensively to
cross-link oligomeric proteins (22). After cross-linking SAA2.2
with glutaraldehyde, its oligomeric state was analyzed by SDS
PAGE (Fig. 1A). The main band seen in lane 2 suggests that the
oligomeric structure of SAA2.2 is consistent with a hexamer. A
10-fold decrease in glutaraldehyde concentration reveals (lane 3)
Fig. 1. Probing the oligomeric structure of SAA2.2. (A) GCL of SAA2.2 (0.1
mgml). The last lane (0.6*) shows cross-linking of a refolded SAA2.2 sample
after it was unfolded in 6 M urea. (B) Size-exclusion HPLC of SAA2.2 at 0.1 and
0.01 mgml. Molecular mass standards (MW stds.) are BSA (67 kDa), ovalbumin
(43 kDa), superoxide dismutase (32 kDa), horse myoglobin (19 kDa), and
ribonuclease A (14 kDa). A 10-fold dilution of the SAA2.2 sample, from 0.10 to
0.01 mgml (10–1.0 M), shows the same retention time, suggesting a sub-
micromolar-to-nanomolar dissociation constant (Kd).
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all of the possible incompletely cross-linked SAA2.2 species
(monomer through hexamer). Lane 5 shows that SAA2.2
unfolded in 6 M urea regains its oligomeric structure after
refolding.
As a complement to the glutaraldehyde studies, SEC was used
to probe the oligomeric state of SAA2.2. Fig. 1B shows a
molecular mass calibration curve based on the retention times of
six different proteins. The retention time (24.5 min) observed for
SAA2.2 at 20°C yields a molecular mass of 55 kDa, which is
lower than expected (70 kDa) but still consistent with the GCL
data. The slight delay (0.75 min) in retention time is likely caused
by the presence of smaller oligomeric species, as suggested by the
observed asymmetric peak (Fig. 1B Inset). The presence of some
monomeric SAA2.2 at 20°C is supported by temperature-
induced denaturation experiments (L.W. and W.C., unpublished
results). At 4°C, SAA2.2 elutes from the SEC column as a sharp
symmetrical peak (Fig. 7, which is published as supporting
information on the PNAS web site, www.pnas.org) with a
retention time slightly faster than BSA, consistent with a ho-
mogenous hexameric structure.
The additional bands shown in GCL experiments and the
asymmetric SEC peak suggest that SAA2.2 may not exist in
solution as a homogenous hexamer under our experimental
conditions. Dynamic light-scattering experiments, which yielded
a hydrodynamic radius for SAA2.2 consistent with a hexameric
structure (3.76 nm; see Fig. 8, which is published as supporting
information on the PNAS web site), also implied some quater-
nary structural heterogeneity. Therefore, we carried out sedi-
mentation-velocity analytical ultracentrifugation experiments,
and the sedimentation-velocity profiles of SAA2.2 at 25°C show
two resolvable boundaries (Fig. 2), suggesting a mixture of at
least two SAA2.2 species under these conditions. Analysis of the
data reveals a sedimentation-coefficient distribution plot [g(s*)]
that is consistent with two sedimenting species in solution.
Fitting the g(s*) plot to a two-sedimenting-species model gave
an excellent fit with sedimentation coefficients and molecu-
lar masses that correspond to a SAA2.2 monomer [s1  1.33 S
(s20,w  1.17 S  0.05), molecular mass (Mw)1  12 kDa,
slow-moving boundary] and hexamer [s2 5.56 S (s20,w 4.9 S
0.06), Mw2  73 kDa, fast-moving boundary], corresponding to
65% monomer and 35% hexamer based on initial absorbance
values.
EM Reveals a Putative Central Channel. Electron micrographs of
SAA2.2 specimens (prepared at 4°C where the hexamer is the
predominant species in solution; unpublished data) showed
particles with a diameter of8 nm that were quite homogeneous
in size and appearance (Fig. 3). Even in the raw images a stain
accumulation in the center of the doughnut-shaped particles was
evident, suggesting the presence of a central cavity or a putative
pore. A similar staining pattern was seen with uranyl acetate
(Fig. 9, which is published as supporting information on the
PNAS web site), suggesting that the stain accumulation in the
center of the particle is not a uranyl formate-specific staining
artifact caused by decreased staining of protein components in
the center of the hexamer. Approximately 7,000 of the doughnut-
shaped 8-nm particles were selected and subjected to image
classification specifying 50 output classes. Most of the resulting
class averages showed few features other than a central stain
accumulation, the putative pore, with a diameter of 2.5 nm
(Fig. 3-1). The lack of fine structure in the averages is not
surprising considering the very small size of the particles.
Nevertheless, one of the class averages indeed showed indica-
tions of the ring being composed of six subunits (Fig. 3-2). This
average, which contained 204 particles, was therefore sixfold-
symmetrized to produce the projection map shown in Fig. 3-3. If
this structure is approximated by six spheres with a diameter of
3.2 nm, and using a protein density of 1.35gcm3 (23), the six
spheres would accommodate a mass of 84 kDa. This value is
relatively close to 70 kDa, the mass expected for a SAA2.2
hexamer.
Central Region of SAA2.2 Is Partially Trypsin-Resistant. Because
stably folded regions of a protein are usually more resistant to
proteolysis, enhanced proteolytic susceptibility may identify
protein regions that are either unfolded or highly flexible (24).
Therefore, we used limited trypsin proteolysis to identify the
regions of SAA2.2 that may comprise the hexamer intersubunit
interface. Trypsin cleaves peptide bonds after the basic amino
acids lysine and arginine, and SAA2.2 has 13 potential cleavage
sites at positions 18, 24, 29, 33, 38, 46, 56, 61, 70, 83, 86, 89, and
102. Partial trypsin digestion of SAA2.2 generated a series of
fragments including a 5-kDa fragment that is partially resistant
to trypsin cleavage (Fig. 4A). The sequence of the various
fragments (Fig. 4 B–F) was determined by liquid chromatogra-
phyMS (Fig. 5; Table 1).
Inspection of a proteolysis time-course experiment (Fig. 4
Fig. 2. SAA2.2 exists as a mixture of hexamer–monomer in equilibrium.
(A) Sedimentation-velocity profiles of a 0.27 mgml sample of SAA2.2. Scans
for analysis were recorded every 1 min; for clarity only eight representative
scans 3 min apart are shown. The velocity data exhibit two resolvable bound-
aries, one corresponding to the monomer and the second boundary corre-
sponding to hexamer. (B) Analysis of the sedimentation profiles in A using the
time-derivative method (dcdt) reveals the presence of two sedimenting
species with an average sedimentation coefficient of 1.5 (1) and 5.4 S (1).
The solid line represents a two-species fit of the data (o) using a Gaussian
function.
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B–F) shows that residues 3839 and 8687 contain the two sites
most susceptible to trypsin proteolysis (B), generating a 5.3-kDa
fragment comprising residues 39–86. This fragment is not
completely degraded after 4 h, suggesting that it is the protease-
resistant fragment observed by SDSPAGE (Fig. 4A). There-
fore, it seems that arginines 38 and 86 are located in solvent-
exposed and flexible regions of SAA2.2. The resulting 1–38
fragment is cleaved rapidly at arginine 18, generating the frag-
ments 1–18 and 19–38. It is interesting that the 1–38 fragment is
preferentially cleaved at position 18. It is possible that the 1–38
and 19–38 fragments may be interacting with the 39–86 frag-
ment to form the corresponding 10- and 8-kDa bands that are
seen by SDSPAGE (Fig. 4A) but not by MS analysis. Also, the
hydrophobic 1–18 fragment may be self-associating to form the
diffuse growing band that runs with an apparent molecular mass
of 36 kDa (Fig. 4A).
Prediction and Experimental Determination of the Secondary Struc-
ture of SAA2.2. The secondary (2°) structure of SAA2.2 was
predicted by using several algorithms from the ProteinPredict
web server (http:cubic.bioc.columbia.edupredictprotein).
These methods are 76% accurate (25), and all gave similar
results. In Fig. 6A we show representative results from PROF,
which is an improved version of PHD, a profile-based neural
network algorithm (26). The algorithm predicted (Fig. 6A) that
SAA2.2 has a probability higher than 0.5 that 45% of its residues
are in an -helical structure and 5% in -structure. The C
terminus of SAA2.2 is predicted to lack any stable 2° structure.
The values in 2° structure content are similar to those deter-
mined by CD for mice (27) and human (28, 29) SAA1, as well
as structure prediction for human SAA1 (29, 30). The far-UV
CD spectrum of SAA2.2 (Fig. 6B) is consistent with the pre-
dicted secondary structure, because its deconvolution using the
Fig. 3. EM and projection structure of SAA2.2. Micrographs revealed doughnut-shaped particles that were homogeneous in size. (1) Representative projection
average (177 particles) of the particle with a diameter of8 nm and a central pore with a diameter of2.5 nm. (2) Projection average (204 particles) that indicated
a sixfold symmetry, which was applied to generate the sixfold-symmetrized average shown in 3. The side length of 1–3 is 20 nm. The circles in the raw image
indicate bright spots that might represent monomeric SAA2.2.
Fig. 4. Time course of limited trypsin digestion of SAA2.2 (0.4 mgml) analyzed by SDSPAGE (A) and RP-HPLC (B–F). The labels on RP-HPLC plots are based on
the MS results (Fig. 5 and Table 1). MW stds., molecular mass standards.
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programs CONTIN, SELCON3, and CDSSTR (18) indicate that the
average content of -helix and -sheet structure in SAA2.2 is
54% and 7% (Fig. 6B), respectively. Reconstructions of the CD
spectra based on the deconvoluted 2° structures produce model
spectra that are virtually identical to the experimental data
(Fig. 6B).
Discussion
Implications of Hexameric SAA2.2 on the 3D Structure of SAA. Our
findings that lipid-free SAA2.2 in solution forms a hexamer
containing a putative central channel, and knowledge of its 2°
structure and solvent-exposed regions provides insight about the
3D structure of the SAA protein family. For instance, the N- and
C-terminal 12 and 17 residues, respectively, are unlikely to
contribute to SAA2.2 hexamerization, because the proline-rich
C terminus is highly solvent-exposed and most likely unstruc-
tured (30), and the N terminus is involved in HDLcholesterol
binding (9, 31). Because residues 30–42 are also exposed in
human and murine SAA (32, 33), the region available for
hexamerization seems limited to residues 13–29 and 43–86,
which are predicted to have a high -helical structure content
(Fig. 6A). The observation that the isolated fragment 39–86 does
not hexamerize (data not shown) and exhibits a lower content of
-structure (20% -helix) than expected (Fig. 6B) further sup-
ports our suggestion that part of the N terminus is required for
hexamer formation.
The EM data (Fig. 3) show that six SAA2.2 subunits assemble
into a hexameric ring (8 nm in diameter) surrounding a putative
central channel (2.5 nm in diameter). Therefore, it seems that
monomeric SAA2.2 interacts via two different interfaces, which
may involve the helical N-terminal residues 13–29 and the central
residues 56–86. Alternatively, it is conceivable that SAA2.2 may
form a hexamer via domain swapping, because this is an efficient
mechanism for a small protein to form higher-order oligomeric
structures (34).
Implications for SAA Function. A better understanding of the
structure of SAA could help elucidate how its various functions
(3) are exerted, regulated, and participating in disease. The wide
range of functions suspected for SAA suggests that it may exist
in more than one oligomeric form, perhaps modulated by ligand
binding or the levels of SAA expression. In particular, it is
conceivable that the drastic increase in SAA expression levels
that occurs during inflammation could determine its oligomeric
state and thereby its function. It is not clear how hexameric SAA
with a central channel would function, especially concerning its
apparently central role of binding HDL and transporting cho-
lesterol. Sequence-specific antibodies raised against synthetic
peptides corresponding to different amino acid regions of human
SAA1 showed that the same epitopes are exposed irrespective of
whether SAA1 is lipid-bound or free in solution (32), suggesting
that the conformation and oligomeric state of SAA is very
similar in both cases. Therefore, SAA may bind to HDL as a
hexamer. A different function for SAA may involve the forma-
tion of toxic channels on the cell membrane of bacteria, thereby
protecting the host against bacterial infection (29). This idea is
supported by the previous observation of E. coli cell lysis caused
by SAA overexpression (8) and the recent report that human
Fig. 5. Liquid chromatographyMS analysis of the SAA2.2 fragments gen-
erated after 30 min of trypsin proteolysis.
Table 1. MS of SAA2.2 fragments generated by limited
proteolysis
Retention
time, min
Assigned
sequence
Expected
mass, Da LCMS, Da
26.68 19–38 2,389.6 2,391.1
26.87 87–103 1,967.2 1,967.9
36.93 39–86 5,293.6 5,295.0
46.62 1–18 2,074.3 2,075.3
49.27 1–103 11,670.7 11,647.8
50.39 1–38 4,445.9 4,447.4
Fig. 6. Secondary-structure analysis of SAA2.2 and SAA39–86. (A) Structure
prediction of SAA2.2 using the PROF algorithm (26) yields the probability of
each residue to be in-helix (pH),-sheet (pE), or loopother (pL) structure. (B)
Far-UV CD spectra (solid lines) of SAA2.2 (0.1 mgml) and SAA39–86 (0.17
mgml) were deconvoluted by using the programs CONTINLL, CDSSTR, and SELCON3
(18). The average secondary structures obtained for SAA2.2 and SAA39–86
were 54% -helix, 7% -structure, and 39% other and 17% -helix, 31%
-structure, and 52% other, respectively. The reconstructed CD spectra from
the deconvoluted secondary structure are in excellent agreement with the
experimental spectra.
Wang et al. PNAS  December 10, 2002  vol. 99  no. 25  15951
BI
O
CH
EM
IS
TR
Y
SAA1 can form voltage-independent ion channels in lipid bi-
layers membranes (29).
Various functions of SAA are linked to regions that are shown
to be flexible or solvent-exposed within the hexamer and there-
fore may not require hexamer formation. The C terminus of
human and murine SAA shows binding affinity to heparan
sulfate (35), a ubiquitous component on the cell surface and
within the extracellular matrix (ECM). The observation that
peptides derived from the C terminus of SAA can also bind to
heparan sulfate in vitro (35) suggests that hexameric SAA is not
required for this interaction. SAA also contains a highly con-
served RGD-like adhesion motif (RGN, residues 39–41 in
SAA2.2) that adheres to various cells including platelets (36).
Peptides derived from SAA and comprising amino acids 29–42
also exhibited platelet-adhesion function, suggesting that hex-
americ SAA is not required for this function. This is consistent
with our proteolysis studies and sequence-specific antibody
experiments (32, 37), which indicate that this region is solvent-
exposed.
Implications of the Hexameric Structure of SAA2.2 in Reactive Amy-
loidosis. Despite three decades of research, the molecular mech-
anism of SAA amyloid formation in AA amyloidosis remains
poorly understood. Studies with peptide fragments (38) and the
full-length protein (39) suggest that the N terminus of SAA
largely determines its amyloidogenicity. Very little is known
about the role of the central region of SAA in AA amyloid
formation, but it is likely to be relevant, because human SAA1
is found predominantly in AA deposits, even though the se-
quence of its N terminus is identical to SAA2 (11, 40). Further-
more, the high probability (0.5) of -structure predicted (Fig.
6A) for the central residues 30–55 and the high -structure
content observed for the SAA2.2 39–86 fragment (Fig. 6B)
suggest that this region may be more important in amyloid
formation than previously believed.
Our discovery that SAA2.2 forms a hexamer in solution may
have implications concerning the amyloidogenicity of SAA
isoforms and the pathogenic mechanism of AA amyloidosis.
Because amyloid fibrils are rich in -sheet structure, the pre-
dominantly -helical secondary structure (Fig. 6) of SAA sug-
gests that the hexamer is not an intermediate precursor to
amyloid formation. We hypothesize that a hexamer-to-monomer
dissociation accompanied by a conformational change that leads
to an increase in -sheet structure may result in the formation
of an amyloidogenic precursor intermediate. Thus, factors that
could destabilize the hexameric structure, including ligand bind-
ing or the amino acid sequence of the SAA isoform, may play a
role in SAA fibrillogenesis. Alternatively, the presence of a
putative central channel in SAA may be relevant to AA amy-
loidosis, as suggested by the accumulating evidence that the
formation of toxic channels or pores on cell membranes may be
involved in the pathology of amyloid diseases (41, 42). Whether
hexameric SAA or a higher oligomerized species play a similar
role in the pathogenic mechanism of AA amyloidosis remains to
be determined.
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